Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 inact mut |
| Therapy | Rucaparib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 inact mut | Advanced Solid Tumor | sensitive | Rucaparib | Phase II | Actionable | In a Phase II trial (LODESTAR), Rubraca (rucaparib) treatment led to an overall response rate of 18% (9/51, 1 complete, 8 partial responses), a disease control rate of 63% (32/51), median progression-free survival of 5.52 months, and overall survival of 13.63 months in advanced solid tumor patients harboring pathogenic BRCA1 (n=17), BRCA2 (n=27) PALB2 (n=14), RAD51C (n=1), and RAD51D (n=2) mutations (PMID: 40632975; NCT04171700). | 40632975 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40632975) | LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | Full reference... |